Accelerating radiopharmaceutical breakthroughs with
high-sensitivity and high-resolution SPECT scanners for transformative research
Imaging the Future of Medicine
Our
Story
About Us
Founded in 2023, MH3D Inc. is a cutting-edge medical device startup dedicated to advancing healthcare through innovation in nuclear imaging. Our flagship technology focuses on an ultrahigh-sensitivity SPECT system designed to revolutionize the early detection and monitoring of cancer, cardiovascular, and neurodegenerative diseases.
Our History
MH3D’s roots are deeply embedded in academic excellence and industry expertise. Our technology is the culmination of over two decades of pioneering research in nuclear imaging detectors from the University of Michigan and the University of Illinois, seamlessly integrated with 20 years of real-world application in the medical imaging industry.
Our Mission
At MH3D, we are committed to pushing the boundaries of medical imaging to enhance diagnostic precision, empower clinicians, and improve patient outcomes worldwide.
Our startup is founded on a vision to revolutionize early detection of cancer, neurological disorders, and cardiovascular diseases through our pioneering nuclear imaging technology. We're committed to supporting pre-clinical and clinical research and enhancing current standards of care with high-precision tools designed for early diagnosis.
Our Product
Alpha-SPECT Mini®
Introducing the MH3D Alpha-SPECT Mini®, the world's first CZT-based pre-clinical SPECT system, offering features unmatched by current market options:
-
Unparalleled energy resolution is perfect for multi-isotope imaging.
-
Ultra-wide stationary field of view needed for comprehensive whole-body dynamic studies of small animals.
-
Fully stationary detector system coupled to a dual-FOV micro-scanning aperture for optimized imaging resolution and ultrahigh sensitivity for a wide range of imaging applications.
-
Fully optimized multi-isotope imaging capability for studying alpha-labeled radiopharmaceuticals (alpha-RPT).
Latest News
Meet the Team
Chairman
Dr. Zhong He, PhD
Dr. Zhong He, Professor in the Department of Nuclear Engineering and Radiological Sciences at the University of Michigan, pioneered the groundbreaking 3D-readout technique, a cornerstone of semiconductor gamma-ray imaging detectors. This innovation enables exceptional energy resolution, superior imaging clarity, and unmatched sensitivity, transforming the field of nuclear imaging technology.
Director of Clinical and Regulatory Affairs, Senior Scientist
Dr. Aileen Ouyang, PhD
Dr. Aileen Ouyang has 9 years of combined academic and industrial experience in the medical device industry. She earned her PhD in Biomedical Engineering from the University of Michigan, Ann Arbor, specializing in clinical affairs and regulatory processes.
​
CEO
Xiaopei Huang, MBA
Xiaopei Huang, CEO of MH3D, holds a Master of Science in Electrical Engineering from the University of Michigan and an Executive MBA from Lawrence Technological University. With a proven leadership and strategic expertise track record, she spearheads MH3D's mission to drive groundbreaking medical innovations, blending technical proficiency with visionary business acumen.
​
Director of Applied Research
Dr. Can Yang, PhD
Dr. Can Yang holds a PhD in Nuclear, Plasma, and Radiological Engineering from the University of Illinois, Urbana-Champaign. His work centers on SPECT imaging system simulations, performance evaluation, and developing high-resolution, high-sensitivity systems for brain imaging and intraoperative use.
CTO
Dr. Ling Jian Meng, PhD
Dr. Ling-Jian Meng, Professor in the Department of Nuclear, Plasma, and Radiological Engineering at the University of Illinois at Urbana-Champaign (UIUC). His research centers on advancing emission tomography imaging technologies, focusing on revolutionizing the diagnosis and monitoring of cancer, cardiovascular diseases, and neurological disorders.
​
Senior Scientist
Dr. Jack Kuchta, PhD
Dr. Kuchta earned his PhD in Nuclear Engineering from the University of Michigan, Ann Arbor. His team is focused on creating next-generation clinical SPECT systems to enhance clinical workflows and improve patient care outcomes.
Supported By
